lpca Laboratories enters into Technology Transfer Agreement with Omexa Formulary
Under this agreement, lpca will grant to Omexa a non-exclusive right to research, develop, manufacture and market an anti-cancer biosimilar for the global market
Under this agreement, lpca will grant to Omexa a non-exclusive right to research, develop, manufacture and market an anti-cancer biosimilar for the global market
Under the arrangement, Dr. Reddy's will have exclusive rights to promote and distribute Sanofi's vaccine brands Hexaxim, Pentaxim, Tetraxim, Menactra, FluQuadri, Adacel and Avaxim 80U
Cipla will be responsible for the distribution of Sanofi India's six CNS brands including Frisium
Centhaquine is a resuscitative agent presently indicated for the treatment of hypovolemic shock by DGCI
Pharma Solutions operates 10 research and development and/or production sites globally
KarXT, Karuna’s lead asset, is a potential first-in-class treatment for Schizophrenia
Winlevi is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older
Cureskin aims to disrupt the large and growing skin and hair care industry in India
India is contributing 13% to the global asthma burden and a disproportionate 43% of the global asthma deaths.
Subscribe To Our Newsletter & Stay Updated